Open Protocols

Protocol Name	Investigatory Role	Biomarkers	Data Collections
Indeterminate pulmonary nodule biomarker clinical utility trial	Involved	0	0
Lung Cancer Risk Trial	Involved	0	0

Closed Protocols

This person has no closed protocols at the present moment.

Publications

Publication Name	PubMed ID	Journal
A deeper evaluation of cytokeratin fragment 21-1 as a lung cancer tumor marker and comparison of different assays.	40329987	Biosens Bioelectron X
A multivariate cell-based assay for blood-based diagnostics enhances lung cancer risk stratification.	40313309	medRxiv
A multivariate cell-based liquid biopsy for lung nodule risk stratification: Analytical validation and early clinical evaluation.	40831733	J Liq Biopsy
Age-related Muscle Fat Infiltration in Lung Screening Participants: Impact of Smoking Cessation.	38106099
Assessing a biomarker platform for stratifying indeterminate pulmonary nodules, protocol for the SPOT IT randomized trial.	42121244	Trials
Assessing the clinical utility of biomarkers using the intervention probability curve (IPC).	38073376
Assessing the transportability of radiomic models for lung cancer diagnosis: commercial <i>vs.</i> open-source feature extractors.	39263016
Association of Health Literacy With Survival in Patients With Lung Cancer.	42548427	CHEST Pulm
Biomarkers for the diagnosis of indeterminate pulmonary nodules: are we there yet?	40950900	J Thorac Dis
Biomarkers in Lung Cancer Screening: a Narrative Review.	37016707	Curr Chall Thorac Surg
Body composition assessment with limited field-of-view computed tomography: A semantic image extension perspective.	37276799	Med Image Anal
Combining Commercial Cancer Protein Biomarkers and Benign Fungal Antibodies Improves Diagnostic Accuracy in Pulmonary Nodules.	42265763	Ann Surg
Cost-effectiveness analysis of artificial intelligence-assisted risk stratification of indeterminate pulmonary nodules.	41785281	PLoS One
Elucidating the role of EPPK1 in lung adenocarcinoma development.	38594604
Extending the value of routine lung screening CT with quantitative body composition assessment.	36303578	Proc SPIE Int Soc Opt Eng
Improving lung cancer diagnosis with cancer, fungal, and imaging biomarkers.	36792410	J Thorac Cardiovasc Surg
Improving Lung Cancer Diagnosis with CT Radiomics and Serum Histoplasmosis Testing.	36535650	Cancer Epidemiol Biomarkers Prev
Improving malignancy risk prediction of indeterminate pulmonary nodules with imaging features and biomarkers.	35870539	Clin Chim Acta
Leveraging Artificial Intelligence as a Safety Net for Incidentally Identified Lung Nodules at a Tertiary Center.	39803962	J Am Coll Surg
Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer.	42233870	Cancer Epidemiol Biomarkers Prev
Longitudinal Analysis of CYFRA 21-1 Levels in Patients with Pulmonary Nodules: Differential Trajectories Between Benign and Malignant Cases and Impact of Tumor Resection.	41646782	medRxiv
Longitudinal analysis of CYFRA 21-1 levels in patients with pulmonary nodules: Differential trajectories between benign and malignant cases.	42335041	PLoS One
Longitudinal Masked Representation Learning for Pulmonary Nodule Diagnosis from Language Embedded EHRs.	40385386	medRxiv
Lung CT harmonization of paired reconstruction kernel images using generative adversarial networks.	38530135
Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.	40387025	N Engl J Med
Optimizing Biomarker Models for Biologically Heterogeneous Cancers: A Nested Model Approach for Lung Cancer.	40072122	Cancer Epidemiol Biomarkers Prev
Performance of Lung Cancer Prediction Models for Screening-detected, Incidental, and Biopsied Pulmonary Nodules.	39907586	Radiol Artif Intell
Potential for trans-pulmonary tumor markers in the early diagnosis of lung cancer: a case report.	39294582	BMC Pulm Med
Radiomic 'Stress Test': exploration of a deep learning radiomic model in a high-risk prospective lung nodule cohort.	40579208	BMJ Open Respir Res
Reducing uncertainty in cancer risk estimation for patients with indeterminate pulmonary nodules using an integrated deep learning model.	36198225	Comput Biol Med
The Intervention Probability Curve: Modeling the Practical Application of Threshold-Guided Decision-Making, Evaluated in Lung, Prostate, and Ovarian Cancers.	35732292	Cancer Epidemiol Biomarkers Prev
The Lung Cancer Prediction Model "Stress Test": Assessment of Models' Performance in a High-Risk Prospective Pulmonary Nodule Cohort.	38737731
The Thoracic Research Evaluation and Treatment 2.0 Model: A Lung Cancer Prediction Model for Indeterminate Nodules Referred for Specialist Evaluation.	37421973
TP53 mutation prevalence in normal airway epithelium as a biomarker for lung cancer risk.	37612638	BMC Cancer
TP53-mutated preneoplastic colonies, adaptive immune response, and risk for lung cancer and COPD.	42495799	Cancer Prev Res (Phila)
Transcriptomics profiling of the non-small cell lung cancer microenvironment across disease stages reveals dual immune cell-type behaviors.	39606240	Front Immunol
Update on biomarkers for the stratification of indeterminate pulmonary nodules.	37244587	Chest
Use of the TREAT 2.0 Model to Create a Web-Based Lung Nodule Calculator for High-Risk Patients.	42266976	Ann Thorac Surg Short Rep
Validation of a Proteomic Signature of Lung Cancer Risk from Bronchial Specimens of Risk-Stratified Individuals.	37760474
Valuing Innovation in the Bronchoscopy Suite.	39601502	Ann Am Thorac Soc

Interests

Validation and measurement of clinical utility in biomarkers, application of machine learning in device and drug surveillance using the electronic health records

As a clinical epidemiologist, Dr. Deppen evaluates and seeks to improve the diagnosis, treatment and outcomes of various cancers. He is an Associate Professor of Thoracic Surgery, co-director of the Vanderbilt’s Thoracic Biorepository and the Early Detection Research Network’s Lung Group National Clinical Validation Center. He also co-leads the MASLAB with Drs. Maldonado and Grogan. Through these roles he has extensive experience in the validation and clinical evaluation of imaging based models, biomarkers, and diagnostic tests with a focus on the early detection of lung cancer. Dr. Deppen’s current research focuses on validation and measurement of clinical utility in biomarkers, application of machine learning in device and drug surveillance using the electronic health records and development of Veteran specific lung cancer screening models, which extensively uses machine learning to link service related and subsequent cancer exposures. In addition to his expertise in lung cancer, he has extensive expertise and publications in the areas of cost effectiveness and implementation science with a focus on the diagnosis and treatment of cancer. Since the beginning of his research career, Dr. Deppen has worked directly with clinicians and scientists to bring evidence to the bedside and improve healthcare across a variety of diseases and their interventions. He is a member of the Early Detection Research Network (EDRN) in the areas of epidemiology and biomarker validation as well as being the co-chair of the biological reference sets working group.

To update protocols, publications, biomarkers, or science data, please contact the Data Management and Coordinating Center.

Site

Vanderbilt University Medical Center

Degree(s)

Ph.D.

Email

steve.deppen@vumc.org

Person ID

3927

EDRN Title

EDRN Principal Investigator

Note

To update contact information, please visit the Data Management and Coordinating Center .